JP Morgan Chase’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.57M | Sell |
70,000
-100
| -0.1% | -$8.24K | ﹤0.01% | 3228 |
|
|
2025
Q4 | $5.98M | Buy |
70,100
+65,400
| +1,391% | +$5.37M | ﹤0.01% | 3147 |
|
|
2025
Q3 | $366K | Sell |
4,700
-71,200
| -94% | -$5.56M | ﹤0.01% | 5195 |
|
|
2025
Q2 | $5.94M | Buy |
75,900
+3,600
| +5% | +$268K | ﹤0.01% | 2995 |
|
|
2025
Q1 | $5.24M | Sell |
72,300
-393,800
| -84% | -$28.2M | ﹤0.01% | 3118 |
|
|
2024
Q4 | $34.5M | Buy |
466,100
+359,700
| +338% | +$25.2M | ﹤0.01% | 1564 |
|
|
2024
Q3 | $7.02M | Buy |
106,400
+45,500
| +75% | +$3.31M | ﹤0.01% | 2933 |
|
|
2024
Q2 | $5.63M | Sell |
60,900
-75,400
| -55% | -$6.68M | ﹤0.01% | 2949 |
|
|
2024
Q1 | $13M | Buy |
136,300
+9,500
| +7% | +$798K | ﹤0.01% | 2246 |
|
|
2023
Q4 | $9.67M | Sell |
126,800
-173,700
| -58% | -$12.1M | ﹤0.01% | 2499 |
|
|
2023
Q3 | $20.8M | Buy |
+300,500
| New | +$24.1M | ﹤0.01% | 1651 |
|
|
2023
Q2 | – | Sell |
-11,500
| Closed | -$951K | – | 7034 |
|
|
2023
Q1 | $951K | Hold |
11,500
| – | – | ﹤0.01% | 4080 |
|
|
2022
Q4 | $858K | Sell |
11,500
-62,500
| -84% | -$4.82M | ﹤0.01% | 4157 |
|
|
2022
Q3 | $6.12M | Buy |
74,000
+41,900
| +131% | +$4.03M | ﹤0.01% | 2568 |
|
|
2022
Q2 | $3.05M | Sell |
32,100
-399,800
| -93% | -$41.4M | ﹤0.01% | 3204 |
|
|
2022
Q1 | $50.8M | Buy |
+431,900
| New | +$48.5M | 0.01% | 1156 |
|
|
2021
Q3 | – | Sell |
-35,300
| Closed | -$3.66M | – | 6560 |
|
|
2021
Q2 | $3.66M | Buy |
+35,300
| New | +$3.33M | ﹤0.01% | 3320 |
|
|
2021
Q1 | – | Sell |
-15,000
| Closed | -$1.37M | – | 6138 |
|
|
2020
Q4 | $1.37M | Hold |
15,000
| – | – | ﹤0.01% | 3747 |
|
|
2020
Q3 | $1.18M | Hold |
15,000
| – | – | ﹤0.01% | 3555 |
|
|
2020
Q2 | $1.04M | Hold |
15,000
| – | – | ﹤0.01% | 3489 |
|
|
2020
Q1 | $943K | Sell |
15,000
-99,000
| -87% | -$7.14M | ﹤0.01% | 3427 |
|
|
2019
Q4 | $8.87M | Sell |
114,000
-72,600
| -39% | -$5.67M | ﹤0.01% | 2210 |
|
|
2019
Q3 | $13.7M | Sell |
186,600
-47,400
| -20% | -$3.33M | ﹤0.01% | 1881 |
|
|
2019
Q2 | $14.5M | Sell |
234,000
-127,200
| -35% | -$7.69M | ﹤0.01% | 1820 |
|
|
2019
Q1 | $23M | Buy |
361,200
+332,700
| +1,167% | +$19M | ﹤0.01% | 1449 |
|
|
2018
Q4 | $1.46M | Buy |
+28,500
| New | +$1.44M | ﹤0.01% | 3506 |
|
|
2017
Q2 | – | Sell |
-216,900
| Closed | -$6.8M | – | 5028 |
|
|
2017
Q1 | $6.8M | Buy |
216,900
+108,900
| +101% | +$3.41M | ﹤0.01% | 2208 |
|
|
2016
Q4 | $3.37M | Buy |
+108,000
| New | +$3.5M | ﹤0.01% | 2737 |
|
|
2016
Q2 | – | Sell |
-128,100
| Closed | -$3.77M | – | 4833 |
|
|
2016
Q1 | $3.77M | Buy |
+128,100
| New | +$3.53M | ﹤0.01% | 2372 |
|
|
2015
Q3 | – | Sell |
-476,400
| Closed | -$11.3M | – | 3963 |
|
|
2015
Q2 | $11.3M | Buy |
+476,400
| New | +$10.8M | ﹤0.01% | 1839 |
|
Other funds holding EW
VCM
VPM
JP Morgan Chase's EW Position: Q1 2026 in Review
JP Morgan Chase reduced its Edwards Lifesciences (EW) stake by 16% in Q1 2026, selling an estimated $353M and leaving 21,744,712 shares worth $1.73B. The position accounts for 0.11% of the portfolio, ranked #182.
JP Morgan Chase first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.22B in Q4 2025. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- JP Morgan Chase held 21,744,712 shares of Edwards Lifesciences worth $1.73B as of Q1 2026.
- JP Morgan Chase sold 4,280,140 Edwards Lifesciences shares in Q1 2026, an estimated $353M.
- Edwards Lifesciences made up 0.11% of JP Morgan Chase's portfolio in Q1 2026, its #182 holding.
- JP Morgan Chase first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Edwards Lifesciences position peaked at $2.22B in Q4 2025.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.